Management of febrile children in the age of the conjugate pneumococcal vaccine: A cost-effectiveness analysis

Pediatrics

Volumn 108, Issue 4, 2001, Pages 835-844

  Lee, Grace M ^a   Fleisher, Gary R ^a   Harper, Marvin B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Conjugate pneumococcal vaccine; Cost effectiveness analysis; Fever; Occult bacteremia

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTEREMIA; BLOOD CELL COUNT; BLOOD CULTURE; CHILD; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; FEVER; HEALTH CARE COST; HUMAN; INFANT; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MENINGITIS; MODEL; OUTCOMES RESEARCH; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; SURVIVAL; TREATMENT PLANNING;

BACTEREMIA; BLOOD; BLOOD CELL COUNT; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEVER; HUMANS; INFANT; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; PNEUMOCOCCAL VACCINES;

EID: 0034784697     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.108.4.835     Document Type: Article

References (65)

1. Bacteremia in febrile children under 2 years of age: Results of cultures of blood of 600 consecutive febrile children seen in a "walk-in" clinic
2. Bacteremia in children: An outpatient clinical review
3. Bacteremia in febrile children seen in a "walk-in" pediatric clinic
4. Practice guideline for the management of infants and children 0-36 months of age with fever without source
5. Strategies for diagnosis and treatment of children at risk for occult bacteremia: Clinical effectiveness and cost-effectiveness
6. Management of infants at risk for occult bacteremia: A decision analysis
7. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era
8. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era
9. National trends in Haemophilus influenzae meningitis mortality and hospitalization among children, 1980 through 1991
10. Three-year multicenter surveillance of systemic pneumococcal infections in children
11. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
12. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
13. Systemic infectious due to Streptococcus pneumoniae relatively resistant to penicillin in a children's hospital: Clinical management and outcome
14. Effect of antibiotic therapy on the outcome of outpatients with unsuspected bacteremia
15. Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia
16. Iatrogenic risks and financial costs of hospitalizing febrile infants
17. Impact of a false positive blood culture result on the management of febrile children
18. Financial and clinical impact of false-positive blood culture results
19. The discrepancy between daily practice and the policy of a decision-analytic model: The management of fever of unknown origin
20. Management of the young febrile child: A commentary on recent practice guidelines
21. Management of the young febrile child: A continuing controversy
22. Clinical guidelines in the setting of incomplete evidence
23. Commentary on practice guidelines
24. Abandoning empirical antibiotics for febrile children
25. Antibiotic therapy in febrile children: Best-laid schemes
26. Efficacy of heptavalent conjugate pneumococcal vaccine in 37,000 infants and children: Impact of pneumonia, otitis media, and an update on invasive diseases - Results of the Northern California Kaiser Permanente efficacy trial
27. Duration of fever and its relationship to bacteremia in febrile outpatients three to 36 months old
28. Occult bacteremia from a pediatric emergency department: Current prevalence, time to detection, and outcome
29. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children
30. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the centers for disease control and prevention's pneumococcal sentinel surveillance system
31. Trends in antimicrobial drug prescribing among office-based physicians in the United States
32. Resistant pneumococci: Protecting patients through judicious antibiotic use
33. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
34. Economic analysis methods and endpoints
35. Efficacy of an observation scale in detecting bacteremia in febrile children three to thirty-six months of age, treated as outpatients
36. Pediatric pneumococcal bone and joint infections
37. Antibiotic administration to treat possible occult bacteremia in febrile children
38. Bacteremia in private pediatric practice
39. Risk factors for development of bacterial meningitis among children with occult bacteremia
40. Do oral antibiotics prevent meningitis and serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia? A meta-analysis
41. Effect of antibiotic therapy and etiologic microorganism on the risk of bacterial meningitis in children with occult bacteremia
42. Outcome of unsuspected pneumococcemia in children not initially admitted to the hospital
43. Treatment of occult bacteremia: A prospective randomized clinical trial
44. Pneumococcal bacteremia in infants and children: A ten-year experience at the Cook County Hospital with special reference to the pneumococcal serotypes isolated
45. Occult pneumococcal bacteremia: What happens to the child who appears well at reevaluation?
46. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis
47. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children
48. Outcomes of bacterial meningitis in children: A meta-analysis
49. Hearing loss during bacterial meningitis
50. Three-year multicenter surveillance of pneumococcal meningitis in children: Clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use
51. Pneumococcal meningitis in children
52. Bacterial meningitis in the United States, 1986: Report of a multistate surveillance study
53. Epidemiology of bacterial meningitis
54. Mortality from pneumococcal meningitis
55. Adverse outcomes of bacterial meningitis in school-age survivors
56. Bacterial meningitis in the United States in 1995
57. Antimicrobial treatment of occult bacteremia: A multicenter cooperative study
58. Intramuscular versus oralantibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia
59. Resource utilization and contaminated blood cultures in children at risk for occult bacteremia
60. Outpatient bacteremia: Clinical findings in children under two years with initial temperatures of 39.5°C or higher
61. Bacteraemia in febrile children presenting to a paediatric emergency department
62. A comparative study of the prevalence, outcome, and prediction of bacteremia in children